ArticleProbiotics and antimicrobial proteins2026
Immunoenhancing Effect of Lactobacillus Kefiranofaciens ZW18 Postbiotic On Cyclophosphamide-induced Immunosuppressed Mice.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postbiotics: emerging bioactive agents in cancer therapy.Cancer biology & medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lactobacillus kefiranofaciens, a lactic acid bacterium isolated from kefir grains, has various probiotic functions, including antioxidant activity, improvement of intestinal health, and immunomodulation. However, the effect of its postbiotic on immune modulation has been rarely reported. In this study, the immunomodulatory activities of the Lactobacillus kefiranofaciens ZW18 postbiotic (Post-ZW18) were investigated both in vitro and in vivo. We discovered that Post-ZW18 increased the phagocytosis of RAW264.7 cells (P > 0.05) and promoted the secretion of cytokines, including NO, IL-6, and TNF-α (P < 0.05), thereby activating the immune response in macrophages in vitro. In vivo, Post-ZW18 reversed cyclophosphamide (CTX)-induced weight loss and organ damage in immunosuppressed mice (P < 0.05), and enhanced the immune response by activating the TLR2/NF-κB signaling pathway, promoting T cell activation and differentiation, and modulating the production of cytokines such as TNF-α, IL-6, and INF-γ (P < 0.05). Furthermore, Post-ZW18 remodeled the intestinal flora, increased the Firmicutes/Bacteroidetes (F/B) ratio (P > 0.05), and upregulated the abundance of bacteria associated with immune activation, specifically increasing unclassified_Lachnospiraceae, Odoribacter, and Lachnospiraceae_NK4A136_group (P < 0.05). In summary, this study provided evidence that Post-ZW18 may serve as a novel dietary supplement for immune regulation.
Indexed as
Identifiers
40512443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.